First Time Loading...

Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266

Watchlist Manager
Suzhou Zelgen Biopharmaceuticals Co Ltd Logo
Suzhou Zelgen Biopharmaceuticals Co Ltd
SSE:688266
Watchlist
Price: 56.62 CNY 2.76% Market Closed
Updated: May 6, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Suzhou Zelgen Biopharmaceuticals Co Ltd

Wall Street analysts forecast Suzhou Zelgen Biopharmaceuticals Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Suzhou Zelgen Biopharmaceuticals Co Ltd is 59.16 CNY with a low forecast of 58.58 CNY and a high forecast of 60.9 CNY.

Lowest Forecast
Wall Street Target
58.58 CNY
3% Upside
Average Forecast
Wall Street Target
59.16 CNY
4% Upside
Highest Forecast
Wall Street Target
60.9 CNY
8% Upside
Lowest
Price Target
58.58 CNY
3% Upside
Average
Price Target
59.16 CNY
4% Upside
Highest
Price Target
60.9 CNY
8% Upside
Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors:
Price Targets
PROB
Probi AB
52% Upside
OVID
Ovid Therapeutics Inc
164% Upside
301047
Sino Biological Inc
44% Upside
T
TSBX
Turnstone Biologics Corp
388% Upside
PROB
Probi AB
52% Upside
OVID
Ovid Therapeutics Inc
164% Upside
301047
Sino Biological Inc
44% Upside
T
TSBX
Turnstone Biologics Corp
388% Upside
T
1875
TOT BIOPHARM International Co Ltd
108% Upside
AMRN
Amarin Corporation PLC
21% Upside
PRAX
Praxis Precision Medicines Inc
157% Upside
NTRA
Natera Inc
10% Upside

Revenue
Forecast

Revenue Estimate
Suzhou Zelgen Biopharmaceuticals Co Ltd

The compound annual growth rate of Suzhou Zelgen Biopharmaceuticals Co Ltd's revenue for the next 4 years is 64%.

N/A
Past Growth
64%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Suzhou Zelgen Biopharmaceuticals Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
15%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Suzhou Zelgen Biopharmaceuticals Co Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
6%
Average Beat
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Suzhou Zelgen Biopharmaceuticals Co Ltd's stock price target?
Price Target
59.16 CNY

According to Wall Street analysts, the average 1-year price target for Suzhou Zelgen Biopharmaceuticals Co Ltd is 59.16 CNY with a low forecast of 58.58 CNY and a high forecast of 60.9 CNY.

What is Suzhou Zelgen Biopharmaceuticals Co Ltd's Revenue forecast?
Projected CAGR
64%

The compound annual growth rate of Suzhou Zelgen Biopharmaceuticals Co Ltd's revenue for the next 4 years is 64%.

ALPHA SPREAD
Join more than 134,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.